A prognostic model for predicting survival in cirrhosis with ascites.
about
Antiviral agents for hepatitis B virus-related cirrhosisKidney Failure and Liver Allocation: Current Practices and Potential ImprovementsHyponatremia in cirrhosis: pathophysiology and managementEffect of the molecular adsorbent recirculating system and Prometheus devices on systemic haemodynamics and vasoactive agents in patients with acute-on-chronic alcoholic liver failureImpact of pretransplant hyponatremia on outcome following liver transplantation.Systematic review: The model for end-stage liver disease--should it replace Child-Pugh's classification for assessing prognosis in cirrhosis?Management of cirrhotic ascitesModerate ascites identifies patients with low model for end-stage liver disease scores awaiting liver transplantation who have a high mortality risk.Hyponatremia and mortality among patients on the liver-transplant waiting listReview article: volume expansion in patients with cirrhosis.Pathogenesis of ascites and predictors of resistance to therapy.MELD scoring system is useful for predicting prognosis in patients with liver cirrhosis and is correlated with residual liver function: a European study.Copeptin as an Indicator of Hemodynamic Derangement and Prognosis in Liver Cirrhosis.Predictive Value of the Model of End-Stage Liver Disease in Cirrhotic Patients with and without Spontaneous Bacterial Peritonitis.Serum cystatin C level is a useful marker for the evaluation of renal function in patients with cirrhotic ascites and normal serum creatinine levels.Volume adaptation in chronic liver disease: on the static and dynamic location of water, salt, protein and red cells in cirrhosis.MELD score and serum sodium in the prediction of survival of patients with cirrhosis awaiting liver transplantationSerum sodium, renal function, and survival of patients with end-stage liver disease.A revised model for end-stage liver disease optimizes prediction of mortality among patients awaiting liver transplantation.Identification of bacterial pathogens in ascitic fluids from patients with suspected spontaneous bacterial peritonitis by use of broad-range PCR (16S PCR) coupled with high-resolution melt analysis.Hyponatremia in cirrhosis and end-stage liver disease: treatment with the vasopressin V₂-receptor antagonist tolvaptan.Risk Factors for Renal Functional Decline in Chronic Hepatitis B Patients Receiving Oral Antiviral Agents.Moderate hyperkalemia in hospitalized patients with cirrhotic ascites indicates a poor prognosis.The association between the serum sodium level and the severity of complications in liver cirrhosisNew model for end stage liver disease improves prognostic capability after transjugular intrahepatic portosystemic shunt.Ascites: pathogenesis and therapeutic principles.Clinical applications of the Model for End-Stage Liver Disease (MELD) in hepatic medicine.Important predictor of mortality in patients with end-stage liver disease.Beta-blockers in cirrhosis and refractory ascites: a retrospective cohort study and review of the literature.Complications of cirrhosis. A 50 years flashback.Survival following the development of ascites and/or peripheral oedema in primary biliary cirrhosis: a staged prognostic model.Cystatin C: a predictor of hepatorenal syndrome in patients with liver cirrhosis.Performance of Disease-Specific Scoring Models in Intensive Care Patients with Severe Liver Diseases.Liver collagen in cirrhosis correlates with portal hypertension and liver dysfunction.Prognostic Models for Survival in Patients with Stable Cirrhosis: A Multicenter Cohort Study.Development and validation of a mathematical equation to estimate glomerular filtration rate in cirrhosis: The royal free hospital cirrhosis glomerular filtration rate.Oxidative breakdown of octanoic acid is maintained in patients with cirrhosis despite advanced disease.Impact of comorbidity on waiting list and post-transplant outcomes in patients undergoing liver retransplantation.Risk factors for development of spontaneous bacterial peritonitis and subsequent mortality in cirrhotic patients with ascites.Predicting Mortality Across a Broad Spectrum of Liver Disease-An Assessment of Model for End-Stage Liver Disease (MELD), Child-Turcotte-Pugh (CTP), and Creatinine-Modified CTP Scores.
P2860
Q24200681-1622E5FC-50CF-4357-84A1-76F0079113A6Q26824109-5CF6611A-272E-4556-AA29-0A2B7F6B8915Q27027861-3CE1D579-AF82-48A5-9D26-A5F2E9659CBAQ27499349-4617044D-AEF4-4EBE-B310-2B18BD0C2469Q33989198-B1E89753-71AF-41C9-97E6-87E75F0854D4Q34469838-C9F43228-7825-4168-871E-1655472854D9Q34475601-559ADCB8-5924-4419-9641-7D1BB2CB4705Q34678891-9B0EB2FA-D0A1-48FB-8231-5BE6FA36B486Q34820619-680143B1-2889-4D04-BC5D-7CDAC97DCDEFQ34992529-BD09532B-E33B-44AA-9C5B-4B02A723DF83Q35020767-2566B357-EC93-4A34-A75C-149E9C8E4CA2Q35595313-D0CC19EF-91B3-4E54-B016-2BE7729D3707Q35778155-29BFA6F9-5E0A-4F23-9FC7-66BAB685A9B7Q35810378-4447AA2F-3632-4B5F-BF3B-E52E0C307660Q35833124-98FA5E77-1D85-4A9E-A101-4194322FCF6EQ35888758-63A6C6EB-976A-4AB8-83D2-86B6945A02D9Q35954077-95E78332-97E0-41E6-A407-ACCC332DC279Q35988332-DE4C27FA-B190-4A15-9657-B171EAA78B6EQ35988340-B70C8EF9-F19C-48AC-9CEA-69ECDC461D58Q36118631-3ECB9528-B3F1-40CE-B145-1D0F33D98FB5Q36319648-05B1389D-225B-4233-9731-65D3594F413BQ36445048-2E60D05C-E152-4C9C-BB4A-2A0D9B3E1E10Q36634933-E2ED76ED-C010-4B1D-B6CB-763A82B37E52Q37233060-4757F364-5AD2-4F46-ACA3-7CFE3DFBD136Q37438532-4F0311A5-98EC-43C6-A469-777863B183E4Q37500169-D66DDC33-FC66-467D-BA21-0A065FBD688EQ37636499-F5D3FB5F-3D94-4028-862B-D69FE483CC4FQ38120248-08417594-E1F8-4EAA-807D-1BA8AD8DC5AFQ38239061-0D4C34B5-C47A-48D1-884C-7A416A8D5510Q38424360-BA280100-6E70-4949-9A25-D2B3B5C6B913Q38937793-8F5F0D1D-FD28-4A33-92E9-5A8B4CDDDC47Q39452131-424EDCF3-792E-47DE-9E85-106137BCCAE9Q40099318-1489319E-C1BE-4CC1-A3ED-DC763D09EA48Q40209617-3B32D34F-77E6-44FD-B9F4-D15FF8D65C22Q40311999-A422AF3E-73A7-4435-B71E-70A97FEF4739Q40516988-C45CD98B-5A56-46BE-9EB1-3EEAD91FCDFCQ40594963-8B04B7AA-BFCE-4BD9-8117-4E83C2AAC681Q41169640-72CEC170-9364-4D6E-B949-A8761F02C795Q41508212-FAEC354D-C466-4E74-83C7-AD1AA7FD844FQ41991508-EC81045D-8C83-4D62-8A9B-86EE5BDE86D1
P2860
A prognostic model for predicting survival in cirrhosis with ascites.
description
2001 nî lūn-bûn
@nan
2001 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
A prognostic model for predicting survival in cirrhosis with ascites.
@ast
A prognostic model for predicting survival in cirrhosis with ascites.
@en
type
label
A prognostic model for predicting survival in cirrhosis with ascites.
@ast
A prognostic model for predicting survival in cirrhosis with ascites.
@en
prefLabel
A prognostic model for predicting survival in cirrhosis with ascites.
@ast
A prognostic model for predicting survival in cirrhosis with ascites.
@en
P2093
P50
P1476
A prognostic model for predicting survival in cirrhosis with ascites
@en
P2093
A Sánchez-Fueyo
G Fernández-Esparrach
P J Ventura
R Bataller
P356
10.1016/S0168-8278(00)00011-8
P577
2001-01-01T00:00:00Z